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In plants and invertebrate animals, RNA silencing is
a form of nucleic acid-based adaptive immunity. By
contrast, jawed vertebrates have evolved complex
protein-based adaptive immunity. Although short in-
terfering RNAs (siRNAs) have been used as artificial
tools to silence viral infection in human cells, it re-
mains unknown whether mammalian viruses naturally
elicit such immunity in vertebral cells. Here, we report
the evidence that HIV-1 encodes viral siRNA precur-
sors in its genome and that natural HIV-1 infection
provokes nucleic acid-based immunity in human cells.
To combat this cellular defense, HIV-1 has evolved in
its Tat protein a suppressor of RNA silencing (SRS)
function. Tat abrogates the cell’s RNA-silencing de-
fense by subverting the ability of Dicer to process
precursor double-stranded RNAs into siRNAs.
Introduction
RNA silencing encompasses posttranscriptional gene
silencing (PTGS) in plants (van der Krol et al., 1990) as
well as RNA interference (RNAi) in animals (Fire et al.,
1998). Common to both types of silencing is the prod-
uction of w21 nucleotide (nt) siRNA, which contains a
19 base-pair (bp) double helix with 2 nt, 3# single-
stranded tails. These siRNAs interfere with the expres-
sion of genes or RNA transcripts, which bear sequence
complementarity. Mechanistically, it is thought that a
long, double-stranded RNA (dsRNA) precursor is first
processed by Dicer, an RNase III-like enzyme, into a
smaller w21 nucleotide siRNA duplex. The small du-
plexed RNA, when unwound by an RNA helicase activ-
ity, is incorporated as a guide sequence into a mul-
ticomponent nuclease complex, the RNA-induced
silencing complex (RISC). RISC can specifically identify
and degrade complementary target RNA, leading to
posttranscriptional gene silencing (Hannon, 2003). In*Correspondence: kj7e@nih.govthis manner, short dsRNA is thought to trigger the
nucleolytic destruction of homologous single-stranded
RNAs (Fire, 1999).
Plants and invertebrate animals lack protein-based
adaptive immunity and do not conserve a typical in-
terferon response. For these less-developed systems,
a biological rationale exists for RNA-based defense
against invading pathogens. RNA silencing is pos-
tulated to be an ancient immune mechanism used by
cells to restrict viruses, transgenes, and transposons
(Carmichael, 2002; Ding et al., 2004; Saksela, 2003).
Consistent with this notion, RNA silencing was first
documented as a natural antiviral response in plants
(Zamore, 2004). More recently, evidence for this type of
functional immunity has been extended to insect cells
(Li et al., 2002; Li et al., 2004).
The emergence of protein-based adaptive immunity
in higher-jawed vertebrates questions whether nucleic
acid-based immunity has become extinguished. That
this defense might still persist comes from findings that
show that in various artificial contexts, RNAi can be
used as a tool for the efficient suppression of gene ex-
pression in human cells (Joost Haasnoot et al., 2003;
McManus and Sharp, 2002; Novina et al., 2002; Silva et
al., 2002; Xia et al., 2002). However, to date, there has
been no evidence that physiological infection of verte-
bral/mammalian cells by viruses produces viral-specific
siRNA, which triggers a RISC-based restriction on for-
eign transcripts. Should a RISC-based restriction be
operative, then the evolution of mammalian viral ge-
nomes would be driven by nucleic acid-based selection
(against dsRNA helices) in addition to classical protein-
and cellular-based adaptive immunities.
The genome of HIV-1 contains a plethora of dsRNA
regions (Mujeeb et al., 1999; Phuphuakrat and Auewar-
akul, 2003; Rana and Jeang, 1999); each, at first glance,
presumptively capable of being processed by Dicer
into siRNA. Interestingly, because HIV-1 is potently lytic
for human cells and replicates in vivo to high-serum
RNA copies (Perelson et al., 1997; Stevenson, 2003),
these findings argue that either this virus cannot physi-
ologically elicit RNAi in human cells or that elicited
RNAi is evaded through genome sequence mutations
(Das et al., 2004) and/or repressed by a virally encoded
suppressor(s) of RNA silencing. To clarify whether RNAi
plays a physiological role for human cells to defend
against HIV-1, we asked three questions. First, does
HIV-1 encode RNA sequences capable of being pro-
cessed into 19 bp siRNAs in human cells? Second, if
such siRNA exists, does it prescribe a sequence-spe-
cific antiviral restriction? Third, if antiviral RNA-based
immunity is triggered by HIV-1, how does the virus
evade this defense?
Here, we show that HIV-1 does encode a virus-specific
siRNA precursor, which elicits antiviral restriction in hu-
man cells. Intriguingly and unexpectedly, we found that
HIV-1 evades elicited RNAi through an SRS function en-
coded in its Tat protein. Tat suppresses an otherwise
effective RNAi restriction through functional abrogation
of the cell’s Dicer activity. Our findings demonstrate,
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fHIV-1-Specific w21 Nt siRNA Is Found
in Infected Cells a
aTo ask if HIV-1 can elicit RNAi, we looked for sequences
within the viral genome capable of composing bona p
(fide 19 bp duplexes. Amongst the two well-known,
highly secondary structured viral sequences TAR and t
hRRE, neither wholly retains a perfect 19 bp duplex.
However, by using computer-directed systematic and c
uprogressive folding over the entire viral genomes, we
found rare examples of perfectly duplexed 19 bp cis w
tsequences (see viral siRNA [vsiRNA]1 through vsiRNA5;
Figure 1A) in HIV-1, HIV-2, and SIV. HIV-1 conserves v
(a single region of duplexes, because vsiRNA1 and
vsiRNA2 are the same sequence shifted from each i
uother by 1 nt pairing (Figure S1 available with this article
online). Because lentivirions are diploid for RNA ge- h
nomes, such 19 bp duplexes can pair either intramolec-
ularly or intermolecularly (see Figure 1A). r
vIs there evidence that the in silico-predicted small
RNA duplexes are physiologically stable and exist in m
mHIV-1-infected cells? First, free energy calculations
suggest that the duplexes are thermodynamically fa- w
nvorable (Figure 1A, see G values). Second, we
checked experimentally whether the predicted vsiRNA1 a
tduplex would exist under physiological buffer condi-
tions and be recognized as substrate by Dicer. We tran- m
pscribed a vsiRNA1 precursor in vitro and asked if it
forms a substrate recognized functionally by Dicer. In- (
tdeed, consistent with such formation, the precursor
vshRNA1 was processed appropriately by Dicer to the v
expected smaller w21 nt vsiRNA form (Figure 1B, com-
pare lanes 1 and 2). We next asked if HIV-1-encoded
vsiRNA is present in HIV-1-infected T cells. By using H
IJurkat and CEM-SS T cells infected with HIV-1, we first
isolated, based on size selection, only those RNAs t
csmaller than 200 nucleotides. The size-selected RNAs
were electrophoresed in polyacrylamide gel and trans- O
sferred to nylon membranes. We then hybridized the
membranes with a vsiRNA1-specific 32P-labeled probe c
sand detected a w21 bp signal (Figure 1C; lanes 2–6, 8,
and 9) not seen in mock-infected cells (Figure 1C, lanes
s1 and 7). The size of this HIV-1 vsiRNA was the same
(Figure 1C, compare lanes 10 and 11) as that produced H
ifrom a previously described 21 bp luciferase-specific
siRNA (Elbashir et al., 2001). Moreover, consistent with a
tits viral origin, the intensity of this 21 bp band increased
in intensity over the course of HIV-1 infection of T cells. s
cAs an additional control, we hybridized HIV-1-infected
cell RNAs with four other 21 bp probes, all with similar s
eGC contents and all from sequences elsewhere in the
viral Env region, in order to verify the specificity of 1
avsiRNA1 (see probes 1–4, Figure 1C). Each probe hy-
bridized, as expected, to the 4 kb HIV-1 Env RNA (see n
aEnv RNA insets, Figure 1D); however, only the vsiRNA
probe detected a 21 bp small RNA (arrow, Figure 1D). e
wWe next wondered if the HIV-1 vsiRNA would func-ionally elicit RNA sequence-specific restriction. In Fig-
re 2, we tested vsiRNA1 and vsiRNA2 for proof of
unction. For this purpose, we constructed target-RNA-
GFP (enhanced green fluorescent protein)-fused tran-
cripts (Figure 2, top) such that cleavage within the
arget-RNA sequence (i.e., arrowed target in the sche-
atics) would separate the ATG translational initiator
rom the downstream EGFP-coding RNA. Target 1-EGFP
nd target 2-EGFP were complementary to vsiRNA1
nd vsiRNA2, respectively. We then asked whether ex-
ression of vsiRNA1 or vsiRNA2 as short hairpin RNAs
shRNAs) in human cells would silence their cognate
arget-EGFP plasmid. Indeed, when we challenged the
airpin, a dose-dependent reduction in green fluores-
ence, up to w65% (Figure 2A, panel 6) or w86% (Fig-
re 2A, panel 3), was seen. As control for specificity,
hen wild-type (wt) EGFP alone (which does not con-
ain an inserted target sequence) was challenged with
siRNA1, we saw no reduction in green fluorescence
Figure 2A, compare panels 8 and 7). These findings
ndicated that the predicted HIV-1-specific siRNA (Fig-
re 1) can indeed restrict complementary transcripts in
uman cells.
To verify the above findings in a physiologically more
elevant setting, we asked whether expression of
shRNA1 would effectively target its cognate HIV-1 Env
RNA. Indeed, expression of vshRNA1 reduced Env
RNA by >80% (Figure 2B, compare lanes 2 and 4),
hereas a sequence-scrambled vshRNA1 control had
o effect on Env mRNA (Figure 2B, compare lanes 3
nd 4). Consistent with this reduction being mediated
hrough a siRNA-RISC complex, coexpression of 2#O-
ethyl oligonucleotides (Hutvagner et al., 2004) com-
lementary to vsiRNA1 rescued Env RNA expression
Figure 2B, lane 5). The Northern blot results are consis-
ent with complementary findings on Env protein re-
ealed by Western blotting (Figure 2B, lanes 6–10).
IV Encodes an SRS
f HIV-1 can induce sequence-specific siRNA silencing,
hen how does the infecting virus escape this perni-
ious restriction to replicate efficiently in human cells?
ne possibility is that, although the virus elicits RNA
ilencing, it also encodes a countervailing SRS. The
lue that HIV-1 may encode a SRS actually came to us
erendipitously.
For some of our ongoing studies, we had made
hRNAs that were specifically targeted to degrade the
IV-1 TAR sequence. In various assays, we used a Tat-
ndependent promoter to drive the expression of either
chimeric TAR-luciferase or TAR-EGFP transcript and
ested whether our TAR-specific shRNAs would enforce
ilencing. Perplexingly, we noticed that our TAR-spe-
ific shRNAs were all ineffective when, by happen-
tance, we included Tat in the assays (Tat is the HIV-1-
ncoded activator of the viral LTR; Rana and Jeang,
999); by contrast, the TAR-specific shRNAs all medi-
ted effective silencing when Tat was not there (data
ot shown). We performed various controls to rule out
ny transcriptional contribution from Tat, and in the
nd, the simplest explanation appeared to be that Tat
orks as an SRS.
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609Figure 1. HIV and SIV Encode Putative siRNA Precursors
(A) Examples of putative siRNA precursors. The five viral siRNAs (vsiRNA) are shown as short hairpins (top, intramolecular pairings) or lined
duplexes (bottom, intermolecular pairings) representing position 6980 of HIV-1A1 (Accession Number U76035) for vsiRNA1, position 7803 of
HIV-1 C (AF290027) for vsiRNA2, position 11166 of HIV-2 CAM2 (DOO835) for vsiRNA3, position 737 of SIV-COL (AF301156) for vsiRNA4, and
position 8937 of SIVagm (M30931) for vsiRNA5. Thermodynamic-free energies are indicated in italics.
(B) Radiolabeled vsiRNA1 was transcribed in vitro from a T7 promoter. 10 l of transcript were incubated with recombinant Dicer overnight
at 37°C, resolved by gel (lane 2) and visualized by autoradigraphy.
(C) RNA enriched for small RNAs (<200 nucleotides) was extracted 24, 48, or 72 hr postinfection (hpi) from HIV-infected Jurkat (lanes 1−6) or
CEM-SS (lanes 7−9) cells and was separated in 15% polyacrylamide-8 M urea gel and hybridized to vsiRNA1-specific probe (top) or to control
5 s rRNA probe (bottom). In the right panel (lanes 10 and 11), HeLa cells were transfected with pNL4-3 or pSilencer-Luc-shRNA. Small RNAs
were purified as described and detected by Northern blotting using a combination of vsiRNA and luciferase-siRNA (Luc-siRNA)-specific
probes. RNA markers are from Ambion (lane 12) or are 5# 32P-radiolabeled 18 mer and 24 mer RNA (lane 13).
(D) Four control probes were selected by SigStb (http://protein3d.ncifcrf.gov/shuyun/rna2d.html) using the following criteria: they recognize
linear HIV sequences, have 52% GC content, and are 21 nucleotides in size. All probes were hybridized to replicate blots.
Immunity
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(A) vshRNA1 and vshRNA2 were tested on target-RNA-EGFP constructs (target1-EGFP, target2-EGFP, top) with target sequences arrowed.
HeLa cells were transfected with target1-EGFP or target2-EGFP, respectively, or control pEGFP with or without vshRNA1 and vshRNA2.
Transfections were normalized by cotransfecting Luc-shRNA as an irrelevant shRNA control (1). Results are shown as a percentage of
inhibition of control EGFP fluorescence.
(B) HeLa cells transfected with vshRNA or a scrambled vshRNA were incubated at 37°C for 16 hr, then cotransfected with a combination of
pNL4-3 + 2#O-methyl oligonucleotides complementary to vshRNA. Env mRNA (left) and protein (right) were evaluated 30 hr later and normal-
ized to 28 rRNA or α-tubulin, respectively (bottom panels).Because Tat binds TAR specifically (Rana and Jeang, e
W1999), its apparent SRS on TAR-luciferase RNA or TAR-
EGFP RNA may arise for its coating of these TAR-con- f
taining transcripts shielding them from TAR-shRNA-
triggered nucleolytic cleavage. To assess whether Tat w
mis a general SRS, we next checked if its expression can
suppress RNAi targeted to non-HIV transcripts, which s
pdo not include a TAR sequence. We employed shRNAs
previously shown by Elbashir et al. (2001) and Grabarek 1t al. (2003) to silence luciferase or EGFP, respectively.
e tested whether Tat would suppress the silencing
unction of these shRNAs.
To check if Tat abrogates luciferase-specific RNAi,
e transfected HeLa cells with pGL2-luciferase plas-
id in combination with two different antiluciferase
hRNAs (Luc-shRNA, Figure 3A). When compared to
GL2 cotransfected with vector alone (Figure 3A, lane
), the two Luc-shRNAs used together knocked down
RNAi during Natural HIV-1 Infection
611Figure 3. Tat Is a General Suppressor of
RNA Silencing
(A and B) HeLa cells cotransfected with
pGL2-luciferase and two separate Luc-shRNA
(1.5 g each) with increasing amounts of
pTat were assayed for luciferase activity nor-
malized to β-galactosidase (A). HeLa cells
were transfected with pEGFP and EGFP-
shRNA with increasing pTat (B). Results are
represented as a percentage of control lucif-
erase activity (A) or EGFP fluorescence (B)
in the absence of shRNA. Values are aver-
ages ± SD from at least three independent
transfections.
(C) HCT116-DNMT cell was incubated for 48
hr with doxycycline (10 g/ml) to activate ex-
pression of DNMT1-shRNA (left). Cells were
transfected with increasing amounts of pTat
prior to doxycycline treatment (right). Pro-
teins (30 g) were loaded and analyzed for
DNMT1 and Tat by Western blotting with
α-tubulin as loading control.luciferase expression by 87.5% (Figure 3A, lane 2). In
such context, we found that an escalated introduction
of Tat in trans abrogated shRNA-mediated luciferase
silencing progressively (Figure 3A, lanes 3–6). Because
Tat has no effect on pGL2 transcription (data not
shown), these results are consistent with a Tat-specific
suppression of shRNA restriction on luciferase mRNA.
To corroborate this finding, we next tested shRNA
targeted to EGFP. When assessed by confocal visual-
ization and quantified by green fluorescent fluorimetry,
transfected EGFP-shRNA capably reduced EGFP ex-
pression by 78% (Figure 3B, panel 2) when compared
to control transfection with vector alone (Figure 3B,
panel 1). Again, this knockdown was reversed when
increasing amounts of Tat were titrated into the shRNA-
transfected cells (Figure 3B, panels 3–5). Thus, at 2 g
of transfected plasmid, Tat sufficed to completely re-
verse shRNA-mediated silencing (Figure 3B, panel 5)
of EGFP.
Others have established a cell line in which doxycy-cline regulates the expression of a DNMT1-targeted
shRNA (Matsukura et al., 2003). To rule out the above
Tat-SRS results being artifacts of complicated multi-
plasmid transfections, we next tested the ability of Tat
to suppress the activity of a doxycycline-regulated,
cell-endogenous DNMT1-shRNA. In Figure 3C, we
found that whereas induction of DNMT1-shRNA by
doxycycline profoundly silenced DNMT1 expression
(Figure 3C, compare lanes 1 and 2), titration of Tat into
cells relieved this silencing (Figure 3C, lanes 4–7). Col-
lectively, the luciferase (Figure 3A), EGFP (Figure 3B),
and DNMT1 (Figure 3C) results support a general Tat
SRS function.
Tat’s SRS Activity Is Distinct from Its
Transcriptional Function
Because Tat is a transcriptional activator, it is possible
that its SRS effect emanated indirectly from the induc-
tion of cellular genes. We next considered whether the
Immunity
612transcriptional function of Tat explains its SRS activity. t
lWe constructed two Tat point mutants and four Tat de-
letion mutants and compared their respective abilities f
(to transcriptionally activate the HIV-LTR (Figure 4A) withFigure 4. Segregation of Tat’s SRS from Its Transcriptional Function
Wild-type (wt) and point- or deletion-mutated Tat were tested for transcriptional (A) and SRS (B) phenotypes.
(A) HeLa HIV-LTR-Luc cells were transfected with a control β-gal plasmid and increasing amounts of wt Tat, TatK51A, or TatK41A. Luciferase
was assessed 48 hr later.
(B) HeLa cells were transfected with pGL2-luciferase, pCMV-β-galactosidase, and a combination of two Luc-shRNAs (1.5 g each) without
or with wt pTat or the indicated mutant Tat.
(C) Cells were transfected with pEGFP, pCMV-β-galactosidase, and EGFP-shRNA without or with the indicated Tat plasmid. Results are
presented as a percentage of inhibition of EGFP fluorescence in the absence of shRNA. All values are from at least three independent transfec-
tions.heir abilities to inhibit shRNAs targeted respectively to
uciferase (Figure 4B) and EGFP (Figure 4C). Results
rom our two Tat point mutants, TatK41A and TatK51A
Figure 4A), were quite instructive. TatK41A is a single
RNAi during Natural HIV-1 Infection
613amino acid change, altering lysine at position 41 to ala-
nine. This mutant was deficient in transcription (Figure
4A) but surprisingly was proficient in suppressing the
restrictions enforced by Luc-shRNA (Figure 4B) or
EGFP-shRNA (Figure 4C). On the other hand, TatK51A
(lysine 51 changed to alanine) was transcriptionally pro-
ficient (Figure 4A) but was wholly deficient in suppress-
ing the silencing function of Luc-shRNAs (Figure 4B) or
EGFP-shRNA (Figure 4C). The finding that TatK41A, a
transcriptionally inactive Tat mutant (Figure 4A), re-
tained an SRS-competent phenotype (Figure 4B, C)
segregates Tat’s SRS activity from its transcriptional
function. These results argue that suppression of RNA
silencing by Tat unlikely flows from its transcriptional
induction of unidentified cellular genes.
Next, we wished to understand which portion of Tat
mediates its SRS function. For this purpose, we con-
structed and tested four Tat deletion mutants: Tat1–38,
Tat38–72, Tat48–72, and Tat55–101 (Figure 4B). (Full-
length Tat is 101 amino acids in length). Tat1–38 and
Tat55–101 mutants did not suppress either Luc-shRNA
(Figure 4B) or EGFP-shRNA (Figure 4C), whereas Tat38–
72 and Tat48–72 did. These results point to Tat’s SRS
function as being contained within its amino acids 38–
72. The fact that neither Tat38–72 nor Tat48–72 is trans-
cripitionally competent (data not shown) provides fur-
ther support that Tat’s SRS activity is separate from its
transcriptional function.
Delineation of Tat’s SRS in a Spreading
HIV-1 Infection
The observation that TatK51A is transcriptionally wt
(Figure 4A) but SRS deficient (Figures 4B and 4C) of-
fered the possibility of constructing a replication com-
petent HIV-1, which is specifically removed for its Tat-
SRS function. Previously, in order to study the function
of Tat mutants in a replication competent setting, we
had devised an approach (Neuveut and Jeang, 1996)
in which the normal copy of Tat in HIV-1 pNL4-3 was
functionally inactivated by point mutation, and Tat func-
tion was replaced with a second copy of Tat (either wt
or mutant) sutured into nef (Figure 5A). To clarify
whether SRS plays a role in HIV-1 replication, we
wanted to create two otherwise isogenic recombinant
HIV-1 genomes in which the normal genomic copy of
Tat is inactivated (i.e., [Tat−]), and a second copy of
either wt Tat (TatWT) or TatK51A mutant is placed into
nef. We predicted that a pNL(TatWT) genome would be
replication (+) and SRS(+), whereas a pNL(TatK51A) ge-
nome would be replication (+) and SRS(−). Thus, a side-
by-side comparison of the growth curves from
pNL(TatWT) and pNL(TatK51A) in human cells would re-
veal the contribution of SRS to HIV-1 replication.
We infected HeLaCD4+ cells with HIV-1 to measure
the effect of SRS on virus replication. With escalating
amounts of virus, wt HIV-1 (pNL4-3; Figure 5B) pro-
duced a peak of virus spread in HeLaCD4+ cells on day
5 after infection (Figure 5B). By using the equivalent of
1 × 106 RT units of inoculating virus, we then compared
side-by-side the replication profiles of pNL(TatWT) and
pNL(TatK51A). In repeated assays (average values from
three independent experiments are shown in Figure5C), we found that pNL(TatWT) replicated consistently
better than pNL(TatK51A), whereas a third recombinant
HIV, pNLTat(−) which lacked Tat’s transcriptional func-
tion, was (as expected) replication defective (Figure
5C). Because pNL(TatWT) and pNL(TatK51A) are iso-
genic except for the single SRS-inactivating K51A
change in the copy of Tat inserted into nef, we interpret
their replication differences to mean that pNL(TatK51A)
is restricted by the cell’s RNAi immunity because it has
a SRS(−) Tat protein. On the other hand, pNL(TatWT)
wards off such immunity through its SRS(+) Tat moiety.
The replication profile differences in Figure 5C were
consistently reproduced in our laboratory. However, the
fairly modest replication differences between pNL(TatWT)
and pNL(TatK51A) suggested that natural HIV-1 infec-
tion may elicit only a mild RNAi restriction in human
cells. This finding is consistent with reports that intrin-
sic immunity to HIV-1 in primate cells arises from the
additive effects of several host factors (Bieniasz, 2004;
Harris et al., 2003; Sayah et al., 2004; Stremlau et al.,
2004). Nevertheless, we wondered if the SRS pheno-
type of the pNL(TatWT) virus could be revealed better
under conditions of more robust RNAi restriction.
To test this possibility, we constructed two separate
shRNAs targeted to either HIV-1 Env or Gag. These
shRNAs were tested and were found to effectively si-
lence Env and Gag, respectively (Figure 5D). We then
challenged HeLaCD4+ cells cotransfected with infectious
genomes of pNL(TatWT) or pNL(TatK51A) with paired
Env-shRNA (Figure 5E) or Gag-shRNA (Figure 5F). Virus
replication in cells was then monitored by measuring
RT production in the culture supernatants. In the set-
ting of shRNA challenge, pNL(TatWT) resisted nucleo-
lytic attack considerably better than pNL(TatK51A) (Fig-
ures 5E and 5F). Thus, at day 2 of infection, Env-shRNA
inhibited the replication of pNL(TatK51A) by w80%,
whereas at the same dose, it inhibited pNL(TatWT) rep-
lication four times less, by w20%. The differences in
virus inhibition became more manifest over time. Thus,
by day 7 of infection, pNL(TatK51A) was entirely re-
stricted by shRNA, whereas minimal inhibition of
pNL(TatWT) was observed (Figure 5E). Results similar
to Env-shRNA were also seen when we challenged
pNL(TatWT) or pNL(TatK51A) with a Gag-shRNA (Figure
5F). En toto, the data in Figure 5 are consistent with
a SRS role contributed by Tat to HIV-1 replication in
human cells.
HIV-1-Encoded siRNA Has Virus-Restricting Activity
As a final measure of the dynamic interplay between
SRS and RNAi, we returned to the consideration of the
HIV-1-encoded siRNA sequences in Figure 1. The find-
ing of a duplexed 19 bp sequence in the entire HIV-1
genome is rare and is restricted to a single region of
the virus. This rarity may be consistent with nucleic
acid-based restriction of HIV-1 being operative in hu-
man cells and selecting against the maintenance of
such duplexes. The fact that one 19 bp duplexed region
remains in the HIV-1 genome argues that this may be a
region that the virus (for unknown reasons) cannot mu-
tate despite RNAi-enforced restriction. Indeed, when
this duplex was examined in the context of 721 discrete
Immunity
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1-Spreading Infection
(A) Schematics of pNLTat(–), pNL(TatWT),
and pNL(TatK51A) genomes (top). All ge-
nomes have the same pNL4-3 backbone with
the tat gene inactivated by two consecutive
stop codons at amino acids 11 and 12 (Neu-
veut and Jeang, 1996). TatWT or TatK51A was
inserted in-frame into nef.
(B) HeLa-CD4 cells were infected with pNL4-3,
pNL(TatWT), pNL(TatK51A), or pNL(Tat–) in
(C), and RT in the supernatant was quantified
over 7 days.
(C) Env- and Gag-shRNAs’ ability to inhibit
their targets was tested in HeLa cells trans-
fected with pCMV-Env or pCMV-Gag-Pol,
respectively. Inhibition of protein was eval-
uated by Western blotting (top) normalized
to actin (bottom). The Env- and Gag-shRNAs
were tested in HeLa-CD4 cells infected with
pNLTatWT or pNLTatK51A in the presence of
Env-shRNA (E) or Gag-shRNA (F). Relative
virus replication, from three independent ex-
periments, was quantified by measuring RT
over 7 days.HIV-1 sequences in the Los Alamos AIDS database, the o
tconservation of base pairing across strains appears
strong (Figure S1). If the vshRNA duplex elicits HIV-1- W
bspecific silencing in cells, then this would be one
reason for the virus to maintain an SRS function in Tat. d
dAlthough in Figure 2 we showed that vshRNA could
elicit sequence-specific RNA restriction on a chimeric i
dEGFP-reporter system and on Env mRNA, we have not
yet shown that such an effect could restrict HIV-1 repli- g
wcation in human cells. To check whether such restric-
tion exists in a whole virus-genome setting, we asked if g
dvshRNA1 would inhibit HIV-1 replication and if Tat could
ameliorate such restriction. In Figure 6A, we challenged t
epNL(TatWT) or pNL(TatK51A) with hairpin version of
vsiRNA1 and assessed the resulting replication profiles. T
wIndeed, similar to Env-shRNA (Figure 5E), vsiRNA1 had
distinct effects on the replication of pNL(TatWT) and r
cpNL(TatK51A). Hence, at days 4 and 5 after infection,
pNL(TatWT) was only modestly inhibited by vsiRNA1, i
cwhereas pNL(TatK51A) was inhibited w80% (Figure 6A;
days 4 and 5). As controls, an unrelated shRNA
targeted to EGFP had no effect on either form of HIV-1 T
T(Figure 6A), and a scrambled version of vsiRNA was
similarly muted in activity (Figure S3). T
mWe performed a separate experiment (in the absencef exogenously added vshRNA) to support the notion
hat virus vsiRNA is operative during HIV-1 replication.
e reasoned that if replication occurs via a balance
etween the actions of vsiRNA and Tat’s SRS (note that
espite Tat expression, residual amounts of vsiRNA remain
etectable; Figure 1C and Figure S2) and if vsiRNAs are
ndeed functional, then such functionality could be
emonstrated by using complementary 2#O-methyl oli-
onucleotides (Hutvagner et al., 2004). Indeed, when
e introduced vsiRNA-complementary 2#O-methyl oli-
onucleotides into HIV-1-transfected cells, we saw a
ose-dependent enhancement of virus replication over
ime (Figure 6B), a finding not found when we used irrel-
vant 2#O-methyl oligonucleotides (data not shown).
his result complements findings in Figure 5C where
e removed Tat’s SRS and observed a commensurate
eduction in replication. Together, both findings are
onsistent with an ambient contest between virus-elic-
ted vsiRNA and virus-encoded SRS during HIV-1 repli-
ation in human cells.
at Inhibits Dicer Activity
he above functional and genetic data serve to indict
at as a suppressor of RNAi. How can this be explained
echanistically? In considering this issue, one experi-
RNAi during Natural HIV-1 Infection
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(A) HeLa-CD4 cells were cotransfected with
pNL(TatWT) or pNL(TatK51A) with or without
vshRNA1 or EGFP-shRNA (as negative con-
trol). Results represent average RT values
from three independent experiments.
(B) HeLa-CD4 cells were transfected with
pNL(TatWT) in the presence or absence of
increasing 2#O-methyl oligonucleotides com-
plementary to vshRNA. RT values from three
independent experiments were quantified
over 6 days.mental observation prompted us to consider whether
Tat acts at an early step of siRNA processing. Up to this
point, we have exclusively employed hairpin versions of
siRNA (i.e., shRNA) for purposes of silencing. shRNA
requires Dicer-mediated processing in order to elicit
RNAi, whereas presynthesized siRNA does not. To bet-
ter understand Tat’s SRS, we wondered if Tat would
also suppress RNAi induced by presynthesized siRNA.
We, thus, compared side-by-side the effect of Tat on
EGFP targeted by presynthesized siRNA or pSilencer-
based shRNA. The results were instructively astonish-
ing. Whereas, Tat rescued against shRNA-based silenc-
ing (Figure 7A, left); it failed to reverse siRNA-based
silencing (Figure 7A, right). Tat had no activity even
when we titrated down the amount of synthesized
siRNA to <100 ng (data not shown). One interpretation
of these results is that the functional target of Tat is
upstream of the siRNA-RISC complex, perhaps at the
level of Dicer.
If the SRS activity of Tat stems from an effect on
Dicer, we asked if this might arise because Tat and/or
HIV-1 infection affected the ambient amounts of Dicer
in cells. To investigate this possibility, we assessed
Dicer expression by Western and Northern analyses.
We saw no steady-state perturbation of intracellular
Dicer levels by either Tat or HIV-1 infection (Figure 7B).
We next asked if Tat directly inhibits Dicer activity. To
answer this question, we checked Tat for effects on the
in vitro processing of long, double-stranded EGFP RNA
(ds-EGFP RNA) by Dicer (Figure 7C). Recombinant
Dicer efficiently processed long ds-EGFP RNA (Figure
7C, lane 1) to short siRNA counterparts (Figure 7C, lane
2) in vitro. However, when whole-cell extract prepared
from HeLa cells transfected with Tat was added intothis assay, siRNA processing by Dicer was reduced by
more than 5-fold (Figure 7C, lane 3). On the other hand,
addition of mock-transfected HeLa cells did not affect
Dicer processing of ds-EGFP RNA (Figure 7C, lane 4).
To verify that the above effect was due to Tat and not
to some uncharacterized factor in the HeLa extract, we
purified recombinant GST-Tat (Figure 7C, right) and
seven GST-Tat mutants (Figure 7D), which were overex-
pressed in E. coli. The purified Tat proteins were then
used in the Dicer assay. In eight side-by-side assays,
we found that purified GST-Tat, Tat20−72, and Tat30−72
capably inhibited Dicer, whereas Tat20−58, Tat30−58,
Tat1−60, Tat1−55, and Tat1−45 did not (Figure 7C, right;
Figure 7D). These results are consistent with the cell-
transfection results in Figure 4; they further confirm that
Tat’s ability to inhibit shRNA-induced silencing maps to
its amino acids 30−72.
Discussion
To date, descriptions of SRS have been limited to plant
viruses (Mallory et al., 2002; Silhavy et al., 2002; Ye et
al., 2003) and animal viruses in invertebrate cells (Dro-
sophila or mosquito [Lindenbach and Rice, 2002]). For
example, tomato bushi tombusvirus and turnip mosaic
virus have been reported to encode viral suppressors
of RNA silencing. These viral suppressors reduce cellu-
lar antiviral effects so that the respective viruses can
accumulate to high titers (Vance and Vaucheret, 2001).
In insect cells, several viral proteins have been shown
to suppress RNA-based antiviral response (Li et al.,
2004). However, to date, proof that jawed vertebrates
with complex adaptive protein-based immunity still re-
tain physiologically relevant nucleic acid-based cellular
Immunity
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(A) HeLa cells were transfected with pEGFP and either pSilencer-EGFP-shRNA or in vitro-synthesized EGFP-siRNA and pTat. Results, from
three independent experiments, are represented as a percentage of control EGFP fluorescence in the absence of siRNA or shRNA.
(B) HeLa cells were transfected with increasing amounts of wt pTat (0.5, 1, or 3 g; left) or 0.5 g of pNL(TatWT), 4 g pNLTat(–), or 2 g
pNL(TatK51A) (right). Dicer protein (Western, top) or RNA (Northern, lower) was assayed. As controls, Tat expression was visualized by
Western blotting, and equal infection was confirmed based on RT. Equal loadings were based on anti-Actin blotting and 28 s rRNA staining.
(C and D) Dicer activity was tested in vitro in the presence of whole-cell extracts from HeLa cells transfected or mock transfected with pTat
(C) or with purified recombinant wt or deletion-mutated Tat proteins (D). 32P-UTP-labeled RNAs were analyzed in a 15% polyacrylamide
gel and were purified by using RNA purification columns and quantified by radioactivity counting (graph, right). Results are from three
independent experiments.defenses has been lacking. Here, we show that HIV-1 a
Oencodes a rare viral siRNA precursor (Figure 1) that elic-
its RNAi-based restriction in human cells (Figure 2B; R
pFigure 6). We also show that HIV-1 Tat is a sequence-
independent SRS used by the virus to combat nucleiccid-based immunity in human cells (Figures 5 and 6).
ur findings suggest that the dynamic interplay between
NAi and SRS remains physiologically conserved from
lants and invertebrates to higher vertebral animals.
The existence of primate lentiviral SRS activity that
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617functions in human cells is consistent with the overall
idea that viruses compete with cells to systematically
counter variously evolved antiviral defenses (Peterlin
and Trono, 2003). Thus, HIV as well as other viruses
(Yewdell and Hill, 2002) encode factors to evade classi-
cal host immune surveillance by downmodulating the
major histocompatibility complex type-I (MHC-I) ex-
pression on cell surfaces (Piguet and Trono, 2001). Fur-
ther, HIV and hepatitis B and C viruses (HBV and HBC)
amongst others have developed means to counter the
cell’s interferon-induced antiviral function (He and
Katze, 2002; Robertson et al., 1996). Intriguingly, even
apparently novel intrinsic cellular antiviral defenses
such as APOBEC3G are circumvented by HIV through
its encoded virion infectivity factor, Vif (Harris et al.,
2003). Altogether, these examples illustrate compel-
lingly the dynamic move-countermove cat and mouse
game played between viruses and their host cells.
That Tat could suppress shRNA activity was unex-
pected. Previously, it was shown that Tat could inhibit
the antiviral interferon-PKR-mediate cellular defense
triggered by long dsRNA, in part, through an RNA bind-
ing-dependent mechanism (Cai et al., 2000). Accord-
ingly, one idea for Tat’s SRS might be for this viral pro-
tein to compete with RISC for binding short siRNAs. If
so, Tat might resemble the p19 protein of the tomato
bushi tombusvirus, which suppresses siRNAs by direct
binding to 21 nt dsRNA (Silhavy et al., 2002; Ye et al.,
2003). However, unlike p19, there is no evidence that
Tat can differentially recognize and bind with high-affin-
ity 21 nt-sized short RNAs (Baulcombe and Molnar,
2004). Hence, a process based on nonspecific RNA
contact (Lichner et al., 2003) without additional recogni-
tion specificity would appear to be easily squelched
and would unlikely have significant physiological rele-
vance. Two discrete lines of evidence in our work di-
rectly argue that Tat’s SRS is not due to RNA binding.
First, the transcriptionally active TatK51A mutant is fully
competent for RNA binding (Jeang et al., 1999) and yet
is entirely lost for SRS activity (Figure 4). This finding is
incompatible with simple RNA binding as an explana-
tion for Tat’s SRS. Second, if Tat works naively through
RNA binding, then one would expect equal activity of
Tat on siRNA as well as shRNA. That Tat suppresses
only shRNA-elicited, but not siRNA-elicited, antiviral
immunity (Figure 6A) argues that it acts at a step of
shRNA prior to siRNA formation (i.e., Dicer processing).
We note that Tat’s SRS activity is not limited to only
shRNAs produced from the pSilencer vector (Figure 3C
and Figure S4). Indeed, our biochemical data implicate
a direct suppression of Dicer’s ribonuclease-directed
processing activity by Tat (Figure 7). We are currently
clarifying the details of Tat-Dicer interaction.
What are the biological implications for HIV-1 if the
virus elicits RNA-based restriction in human cells? We
think that this cellular defense may have contributed to A
shaping the evolution of the viral genome. Indeed, we
are struck by the fact that existence of perfect-paired
duplexes in HIV-1 sequences is rare (Figure 1). Although
there are stability reasons why RNA viruses might pre-
fer a doubled-stranded nature, the rarity of perfect
duplexes in the HIV-1 genome suggests that this virus
might have evolved sequence changes in order to es-
cape ancient RNAi restriction (Das et al., 2004). Indeed,although changes in coding regions of HIV-1 might
be explained by viral responses to classical immune
selection, sequence evolution in viral noncoding re-
gions may, in fact, be guided by nucleic acid-based
immunities. The apparent conservation of a rare double-
stranded region of vsiRNA1 in HIV-1 (Figure S1) sug-
gests that this duplex may somehow have been re-
tained despite nucleic acid-based restriction. We
emphasize that currently we have no understanding as
to the reason for this retention, and future experiments
are needed to answer this question.
Whether a natural antiviral role for siRNA exists in
vertebrates has been questioned (McManus, 2004;
Voinnet, 2005). Here, we present evidence that such an
antiviral role may be rare and modest in magnitude for
vertebrates but can be demonstrated in HIV-1-infected
human cells. Our finding that Tat is a SRS also helps
explain a long-standing biological observation as to
why Tat(−) HIV-1 genomes, which are fully restored for
transcription by using alternative transcriptional activa-
tors, fail to spread productively in human cells (Dayton
et al., 1986; Fisher et al., 1986). Indeed, our data recon-
cile that paradox by postulating that infection by HIV-1
elicits an antiviral defensive RNAi in human cells. Un-
less such induced RNAi is quelled by the virus through
its Tat factor, viral replication may not proceed with
success. Accordingly, viruses defective in RNAi-sup-
pressing function (i.e., Tat[−] HIV-1 genomes) are repli-
cation disabled even if their transcription can be fully
reconstituted via heterologous means (Huang et al.,
1994).
Our results raise a challenge to proposed RNAi thera-
peutic strategies as applied to HIV-1. Published find-
ings in model cell culture systems where targeting HIV
with siRNA induces a significant initial replication inhi-
bition seem to lose efficacy over time (Boden et al.,
2003; Novina et al., 2002). One possible explanation, as
mentioned above, is that the high mutability of HIV-1
renders it elusive for sequence-specific RNA targeting
(Boden et al., 2003). Another consideration raised by
our current findings is that virally encoded SRS activity,
whether through Dicer or through specific recognition
of siRNA, eventually wins out when production of elic-
ited RNAi begin to wane. In considering the Dicer-inhib-
itory activity of Tat shown here, we suggest that for
applications of RNAi to HIV-1 therapy the use of prepro-




pCMV-Env and pCMV-Gag-pol are the pCMV-env-CTE (from D. Re-
kosh) and the pCMVNL-gag-pol-CTE (E. Freed) described else-
where. Both contain the MMPV constitutive transport element that
allows Rev-independent expression. pTAR-EGFP was constructed
by PCR amplifying EGFP using 5#-GGATCCACGGTACTAGCT
CT-3# and 5#-TGATCTAGAGTCGCGGCCGCTTTACTTGTACA-3#
and cloning into BamHI-NotI sites of pEGFP-N1 (Clontech). TAR
was cloned upstream into EcoRI-BamHI sites. pTat101wtFLAG
(Kiernan et al., 1999) was used to generate pTat K41A and pTat
K51A by site-directed mutagenesis (QuikChange, Stratagene). All
plasmids were sequenced.
Computer Analyses of HIV and SIV Genomes
All HIV-1, HIV-2, and SIV sequences were from the HIV database
(http://hiv-web.lanl.gov). RNAMOT (Laferriere et al., 1994) was used
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618to search for the RNA duplexes in progressive 20 bp stretches by r
lusing criteria that the minimal duplex stem is 21 bp with <2 mis-
matches, and the distance between the nt i and j in the terminal
base-pairing S(i,j) is >3 nt and <900 nt. The detected duplexes were




Virus stock was prepared by transfecting HeLa cells. Virus was
quantified by reverse transcriptase (RT; Willey et al., 1988); 106−107
cpm RT units were used to infect 5 × 106 Jurkat or CEM-SS cells. A
After 2 hr of exposure to virus, cells were washed and resuspended
in RPMI. After 24, 48, or 72 hr, supernatant RT was quantified, and W
cells were harvested for RNA. HeLa-CD4 cells were transfected s
with 0.5 g of HIV pNL4-3 (TatWT) or 2 g of pNL4-3 (TatK51A) or D
infected with 104−106 RT units of HIV. Assays were performed 48
hr after transfection in at least three independent experiments and
Rcontinued for 7 days in the case of HeLa-CD4 cells.
R
A
Small RNA Extraction and Northern Analysis P
RNAs <200 nucleotides were isolated by using mirVana miRNA Kit
R(Ambion). RNAs were separated on 15% acrylamide-8 M urea gel
and electro transferred for 1 hr at 200 mA to nylon membrane. After
BUV crosslink, membranes were prehybridized for 1 hr at 68°C in
aUltrahyb (Ambion) and incubated overnight at 37°C with probes.
2Membranes were washed at room temperature and autoradio-
graphed. B
a
BsiRNA and shRNA Constructions
HOligonucleotides corresponding to the siRNA hairpin targeting are






TTT-3#) (Capodici et al., 2002), Env (5#-CAGGCCTGTCCAAAGGTAT H
CCTTCAAGAGAGGATACCTTTGGACAGGCCTGTTTTTT-3#), e
GL2luciferase1 (5#-AAGTGTTGTTCCATTCCATTTCAAGAGAATGG C
AATGGAACAACACTTTTTTTT-3#), GL2luciferase2 (5#-CGTACGCGG t
AATACTTCGATTCAAGAGATCGAAGTATTCCGCGTACGTTTTTT-3#)
D(Elbashir et al., 2001), EGFP (5#-GTGGAGAGGGTGAAGGTGAT
rGCCTCGAGGCATCACCTTCACCCTCTCCACTTTTTT-3#) (Grabarek
det al., 2003), and vsiRNA1 (5#-#TCCCTTTGTTGTAGCGAGCTTCAA
iGAGAGCTCGCTACAACAAAGGGATTTTTT-3#), and the reverse cor-
Dresponding sequences were synthesized. After annealing, oligonu-
Wcleotides were cloned in ApaI-EcoRI sites of pSilencer-1.0-U6 vec-
ttor (Ambion). The in vitro synthesized Luc- and EGFP-siRNA




aFluorescence was visualized by using a Zeiss LSM410 laser scan-
Rning confocal microscope. Fluorimetry used assay buffer (100 mM
4Hepes, 0.5% Triton X-100, 1 mM CaCl2, and 1 mM β-mercapto-
Fethanol) and was quantified with a QuantaMaster spectrofluorime-
3ter by analyzing emission at 510 nm after excitation at 490 nm
during 10 s (Photon Technology International). Luciferase used 1× F
luciferase lysis buffer (Promega) and light measurement with an M
Opticom II luminometer (MGM Instruments). β-galactosidase activ- d
ity was measured with Galacto-Star (Tropix, Bedford, Mass.). All 8
reporter values represent averages ± SD from at least three inde- F
pendent transfections. L
R
vIn Vitro Assay of Dicer Activity
G1 g of 700 bp (32P)UTP-labeled dsRNA was incubated for 16 hr
Gwith 1 U of recombinant Dicer in the presence of wt, point- or dele-
dtion-mutated Tat proteins, or cytoplasmic extracts of transfected
cHeLa cells. RNA products were analyzed by using 15% native poly-
acrylamide gel. siRNA was further purified by using RNA purifica- H
Jtion columns (Gene Therapy Systems) and quantified by countingesidual radioactivity. All values represent average ± SD from at
east three independent experiments.
upplemental Data
upplemental Data contain four figures and are available with this
rticle online at http://www.immunity.com/cgi/content/full/22/5/
07/DC1/.
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